Diana Tea Company Ltd has successfully passed all eight resolutions at its 115th Annual General Meeting held on September 11, 2026. Key approvals include the issuance of equity convertible warrants on a preferential basis, the re-appointment of Mrs. Sarita Singhania as Whole-Time Director, and the expansion of borrowing and investment limits. These approvals provide the company with enhanced financial flexibility and updated corporate governance frameworks, setting the stage for future capital infusion plans.
Diana Tea Company Shareholders Clear Eight Key Resolutions
All eight proposed resolutions passed with the requisite majority at the 115th Annual General Meeting.
Shareholders officially greenlit the issuance of equity convertible warrants and updated corporate borrowing limits.
Reader Takeaway: The company gains financial flexibility via warrant issuance and expanded borrowing limits, clearing the path for growth.
What just happened
Diana Tea Company Ltd conducted its 115th Annual General Meeting on September 11, 2026, through video conferencing. Shareholders voted in favor of all eight agenda items presented by the management. The outcomes cover operational, financial, and constitutional matters, including the re-appointment of Mrs. Sarita Singhania as Whole-Time Director.
Why this matters
The approval for the issuance of equity convertible warrants on a preferential basis is the most significant development for investors. This provides the company with a clear path toward future capital infusion. Additionally, the enhancement of limits under Section 180(1)(a) and Section 186 grants the board greater leeway for asset management, borrowing, and strategic investments.
Governance and Constitutional Changes
The company successfully updated its foundational documents by adopting a new Memorandum of Association and Articles of Association to ensure full alignment with the provisions of the Companies Act, 2013. This move modernizes the company’s internal regulatory framework.
What to track next
Investors should look for forthcoming regulatory filings that disclose the specific terms, pricing, and allottees associated with the newly approved preferential equity convertible warrants. These details will clarify the impact on equity dilution and the intended use of the raised capital.
